Press Releases



 
Press Releases
  Date Title View
Dec 11, 2017
REDWOOD CITY, Calif., Dec. 11, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results of 10 studies that reinforce the unmatched value of the Oncotype DX Breast Recurrence Score® test and Oncotype DX® DCIS Score™ test in optimizing patient treatment across the breast cancer disease continuum. The data were ...
PDF
Dec 6, 2017
REDWOOD CITY, Calif., Dec. 6, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced a multi-year research collaboration agreement with Janssen Pharmaceuticals to evaluate the Oncotype DX Genomic Prostate Score™ (GPS™) test for their prostate cancer drug pipeline.  As part of the agreement, Genomic Health will test sam...
PDF
Nov 30, 2017
REDWOOD CITY, Calif., Nov. 30, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present 10 Oncotype DX® studies at the 40th San Antonio Breast Cancer Symposium (SABCS), which is being held December 5-9, 2017. Presentation highlights include: Positive results from an international validation study...
PDF
Nov 28, 2017
REDWOOD CITY, Calif. and CLEVELAND, Nov. 28, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX), the world's leading provider of genomic-based diagnostic tests, and Cleveland Diagnostics, Inc., a biotechnology company focused on developing next-generation diagnostics technology for the detection of cancers, today announced an exclusive licens...
PDF
Nov 21, 2017
REDWOOD CITY, Calif., Nov. 21, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 29th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, November 28, 2017 at 10:30 a.m. Eastern Time. To access the live and subsequently archived webcast of the presentation, go to the Inve...
PDF
Nov 8, 2017
REDWOOD CITY, Calif., Nov. 8, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended September 30, 2017. Total revenue was $83.8 million in the third quarter of 2017, compared with $82.3 million in the third quarter of 2016, an increase of 2 percent. Revenue was n...
PDF
Nov 1, 2017
REDWOOD CITY, Calif., Nov. 1, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, November 8 at 4:30 p.m. Eastern Time to discuss its third quarter 2017 financial results. The call and webcast will follow the release of the third quarter financial results af...
PDF
Sep 13, 2017
REDWOOD CITY, Calif. and MECHELEN, Belgium, Sept. 13, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests  and Biocartis Group NV (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announced an exclusive agreement to develop an in vitro diagnostic (IVD)...
PDF
Sep 11, 2017
REDWOOD CITY, Calif., Sept. 11, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of new data that provide additional evidence of the unmatched value of the Oncotype DX Breast Recurrence Score® test in accurately predicting outcomes in early-stage breast cancer patients. The data were presented at the 20...
PDF
Aug 31, 2017
REDWOOD CITY, Calif., Aug. 31, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from four Oncotype DX Breast Recurrence Score® test studies at the European Society for Medical Oncology (ESMO) 2017 Congress. The conference takes place September 8-12 at the IFEMA, Feria de Madrid, in ...
PDF
1
...
NextLast